Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Sun Pharmaceutical Industries Limited200 enrolled

Overview

This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to tildrakizumab during pregnancy to treat an approved indication. The pregnancy registry cohort study will be conducted by the Organization of Teratology Information Specialists (OTIS), which is a network of university and health department based information centers serving pregnant women and healthcare providers throughout North America. These services provide a basis for collaborative research such as this Registry. These Services located throughout the United States (US) and Canada will serve as a source of referrals not only for tildrakizumab-exposed pregnancies but also for similarly ascertained disease-matched comparison pregnant women who have not used tildrakizumab in pregnancy. The target follow-up period will be until end of pregnancy and 1 year of age for live born infants.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Pregnancy Related

Interventions

Pregnant women exposed to tildrakizumabDRUG

Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Cohort 1: Tildrakizumab-Exposed Cohort 1. Pregnant women 2. Exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period up to and including the end of pregnancy 3. Agree to the conditions and requirements of the study including the interview schedule, and release of medical records Cohort 2: Disease-Matched Comparison Cohort 1. Pregnant women 2. Diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible 3. No exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy 4. Agree to the conditions and requirements of the study including the interview schedule, and release of medical records Exclusion criteria: Cohort 1: Tildrakizumab-Exposed Cohort: 1. Women who have first contact with the project after prenatal diagnosis of any major structural defect 2. Women who have enrolled in the tildrakizumab cohort study with a previous pregnancy (women may only enroll once in the Tildrakizumab Pregnancy Study) 3. Women who have used tildrakizumab for an indication other than a currently approved indication 4. Retrospective enrollment after the outcome of pregnancy is known Cohort 2: Disease-Matched Comparison Cohort 1. Women who have first contact with the project after prenatal diagnosis of any major structural defect 2. Exposure to tildrakizumab anytime during the current pregnancy 3. Women who have enrolled in the tildrakizumab cohort study with a previous pregnancy (women may only enroll once in the Tildrakizumab Pregnancy Study) 4. Retrospective enrollment after the outcome of pregnancy is known

Outcomes

Primary Outcomes

Major structural defects in children

defined and classified using the US Centers for Disease Control and Prevention (CDC) coding manual that is used for the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of major structural defects

Time frame: Up to 1 year of age

Secondary Outcomes

Spontaneous abortion/miscarriage

defined as non-deliberate fetal death that occurs prior to 20.0 weeks post-last menstrual period

Time frame: 20 weeks post-last menstrual period

Stillbirth

defined as non-deliberate fetal death anytime in gestation at or after 20.0 weeks post-last menstrual period

Time frame: from 20 weeks post-last menstrual period to end of pregnancy

Elective termination/abortion

defined as deliberate discontinuation of pregnancy through medication or surgical procedures

Time frame: At the end of pregnancy or through 9 month pregnancy period

neonatal/infant death

defined as any death in a live born infant during the first 6 months of age

Time frame: 6 months of age

Small for gestational age

defined as birth size (weight, length, or head circumference) less than or equal to the 10th centile for sex and gestational age using standard pediatric CDC growth curves for full term or preterm infants

Time frame: at birth

Postnatal growth deficiency

defined as postnatal size (weight, length or head circumference) less than or equal to the 10th centile for sex and age using standard pediatric growth curves and adjusted for postnatal age for premature infants if the postnatal measurement is obtained at less than 1 year of age

Time frame: Up to 1 year of age

Malignancies in live born children

defined as any malignancy reported in an infant within the first year of life

Time frame: Up to 1 year of age

Hospitalization in live born children

defined as any hospitalization of the infant within the first year of life after discharge following delivery

Time frame: Up to 1 year of age

Postnatal serious or opportunistic infection in live born children

defined as any infection resulting in hospitalization, X-ray proven pneumonia, neonatal sepsis, meningitis, osteomyelitis, bacteremia, septic arthritis, abscess, mycobacteria infections, invasive fungal infection including histoplasmosis, coccidiomycosis, candidiasis, aspergillosis, and blastomycosis, pneumocystis jirovecii infection, systemic cytomegalovirus, herpes zoster and herpes simplex infection, listeria infections, and Legionella infection.

Time frame: Up to 1 year

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts